


PHARMACEUTICAL 2020











PHARMACEUTICAL 2020



ENANTA PHARMACEUTICALS INC Rank 13 of 362



The relative strengths and weaknesses of ENANTA PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ENANTA PHARMACEUTICALS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 393% points. The greatest weakness of ENANTA PHARMACEUTICALS INC is the variable Research and Development, reducing the Economic Capital Ratio by 25% points.

The company's Economic Capital Ratio, given in the ranking table, is 270%, being 573% points above the market average of -303%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 401,848 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 22,609 |
| Liabilities, Non-Current | 3,100 |
| Other Assets | 77,054 |
| Other Compr. Net Income | 544 |
| Other Expenses | -826 |
| Other Liabilities | 1,628 |
| Other Net Income | 8,819 |
| Property and Equipment | 10,927 |
| Research and Development | 142,213 |
| Revenues | 205,197 |
| Selling, General and Administrative Expense | 26,246 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 489,829 |
| Liabilities | 27,337 |
| Expenses | 167,633 |
| Stockholders Equity | 462,492 |
| Net Income | 46,383 |
| Comprehensive Net Income | 46,655 |
| Economic Capital Ratio | 270% |

